Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Macrophage engulfing bacteria 3d illustration © Shutterstock

A new study by researchers at the Kennedy Institute of Rheumatology, NDORMS and Translational Gastroenterology Unit, University of Oxford, has identified potential new therapeutic targets for the treatment of inflammatory bowel disease (IBD).

Published in Nature Medicine, the research has defined a subset of patients with IBD that do not respond to several current therapies.

The research set out to explore the different cellular and molecular processes that underlie inflammation in the tissue of patients who do not respond to treatment. They found that patients with ulcers who had increased activation of fibroblasts and expansion of the vascular system, and a high number of neutrophils in the inflamed intestine responded poorly to treatments.

Fibroblast activation and accumulation of neutrophils were driven by increased signalling from the cytokine IL-1R, which suggests that blocking IL-1 may benefit those individuals with deep ulceration and who do not respond to several different current therapeutics.

Patients with IBD saw a breakthrough when anti-TNF therapy was shown to be an effective treatment, but up to 40% of patients with IBD don’t respond to the therapy.

“anti-TNF is not effective in all patients with IBD,” said Professor Fiona Powrie, Director of the Kennedy Institute and lead researcher on the study. “One of the major challenges has been to understand the cellular mechanisms and inflammatory pathways that underlie resistance to treatment in certain individuals but not others. 

“These latest findings are an exciting step forward as they indicate an alternative treatment for a subset of patients who do not respond to current therapies as well as a basis for personalised targeting of medicines to treat this chronic inflammatory condition.”

'As a specialist in treating ulcerative colitis and Crohn's disease', said Professor Simon Travis, 'it is hugely exciting to find tools that can help us to select the best possible treatment for each individual. This means that we will no longer be in the realm of trial and error, but able to precision-target treatment based on the dominant driver of inflammation in that person.'  

 

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.